Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Edesa Biotech ( (EDSA) ) has issued an update.
On February 24, 2026, Edesa Biotech reported additional positive Phase 3 data for paridiprubart from a 278-patient study, showing a statistically significant reduction in adjusted 28-day mortality to 24% from 33% versus placebo across the full treatment population. Benefits were consistent across severity levels and comorbidities, with higher clinical improvement rates by Day 28 and a safety profile comparable to placebo, reinforcing the drug’s potential in critical care settings.
Exploratory analyses showed that in 174 non-ventilated patients, paridiprubart plus standard of care cut adjusted 28-day mortality to 15% from 23%, and mortality reductions of 30%-36% were observed in patients with pneumonia, acute kidney injury and sepsis. Building on these results, Edesa has filed provisional patents for using paridiprubart in these indications, while parallel government-funded trials and manufacturing scale-up support the company’s late-stage development and commercial-readiness strategy.
The most recent analyst rating on (EDSA) stock is a Sell with a $0.73 price target. To see the full list of analyst forecasts on Edesa Biotech stock, see the EDSA Stock Forecast page.
Spark’s Take on EDSA Stock
According to Spark, TipRanks’ AI Analyst, EDSA is a Neutral.
The score is held down primarily by weak financial performance (no revenue, ongoing losses and cash burn) and bearish technicals (below all major moving averages with negative MACD). Valuation provides limited support due to a negative P/E and no dividend yield data.
To see Spark’s full report on EDSA stock, click here.
More about Edesa Biotech
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing first-in-class biologic therapies, including the anti-TLR4 antibody paridiprubart. The company focuses on severe inflammatory and infectious conditions, supported by government funding and core composition-of-matter patents that extend into the 2030s.
Average Trading Volume: 82,622
Technical Sentiment Signal: Sell
Current Market Cap: $8.29M
See more insights into EDSA stock on TipRanks’ Stock Analysis page.